FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 337:349-350 July 31, 1997 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Spirito, P. PubMed Citation

To the Editor: With regard to the excellent review article by Spirito et al. (March 13 issue),¹ we wish to report data on percutaneous transluminal septal myocardial ablation, which Sigwart introduced in 1995 as a new option for the treatment of highly symptomatic patients with hypertrophic obstructive cardiomyopathy.² Since January 1996,³ we have used this technique of nonsurgical myocardial ablation by alcohol-induced occlusion of the first septal perforation in 56 highly symptomatic patients (mean [±SD] New York Heart Association functional class, 2.7±0.6). The left ventricular outflow tract gradient was reduced in 93 percent of patients (eliminated in 27 percent, reduced . . . [Full Text of this Article]

References

This article has been cited by other articles:

• KNIGHT, C. J (2000). Five years of percutaneous transluminal septal myocardial ablation. Heart 83: 255-256 [Full Text]  
• Faber, L., Seggewiss, H., Gleichmann, U. (1998). Percutaneous Transluminal Septal Myocardial Ablation in Hypertrophic Obstructive Cardiomyopathy : Results With Respect to Intraprocedural Myocardial Contrast Echocardiography. Circulation 98: 2415-2421 [Abstract] [Full Text]